Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 14/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1296178 | 0.86 | MEN1 (0.48) | ALDH1A1CES2MEN1CYP1A2POLB | |
| SCHEMBL1295248 | 0.76 | LMNA (0.41) | ALDH1A1MEN1POLBKMT2ASMN1; SMN2 | |
| SCHEMBL1296133 | 0.74 | AKR1C3 (0.42) | AKR1C3AKR1C2MEN1CYP2C9KMT2A | |
| SCHEMBL1295824 | 0.72 | HDAC4 (0.41) | CES2MEN1KMT2A | |
| SCHEMBL1295561 | 0.72 | ACP3 (0.40) | SMN1; SMN2 | |
| SCHEMBL1295519 | 0.72 | TRPM8 (0.43) | — | |
| SCHEMBL8692384 | 0.71 | AKR1C3 (0.63) | AKR1C3AKR1C2ALDH1A1CES2MEN1 | |
| SCHEMBL1296267 | 0.71 | FFAR1 (0.46) | AKR1C3AKR1C2 | |
| SCHEMBL1295357 | 0.70 | ALDH1A1 (0.38) | ALDH1A1POLBCYP3A4KMT2A | |
| SCHEMBL7533204 | 0.69 | PNMT (0.49) | ALDH1A1CES2MEN1CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269811-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | FASTRACK PHARMACEUTICALS, INC. | 2011-11-03 | — | — | US | disclosed |
| US-20090203764-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | FASTRACK PHARMACEUTICALS, INC. | 2009-08-13 | — | — | US | disclosed |
| US-20070293548-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases | LA JOLLA PHARMACEUTICAL COMPANY | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293548-A1 | Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases | VCAM1, AOC3, AOC2 | AKR1C3 1553/4885AKR1C2 1980/4885TACR1 1291/4885 |
| US-20110269811-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | VCAM1, AOC3, AOC2 | AKR1C3 1553/4885AKR1C2 1980/4885TACR1 1291/4885 |
| US-20090203764-A1 | INHIBITORS OF SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) AND VAP-1 MEDIATED ADHESION USEFUL FOR TREATMENT AND PREVENTION OF DISEASES | VCAM1, AOC3, AOC2 | AKR1C3 1553/4885AKR1C2 1980/4885TACR1 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.